Experienced biotech executive takes helm of promising T-Cell Therapy company as it moves several programs toward clinical testing
HAMILTON, Ontario & AUSTIN, Texas–(BUSINESS WIRE)–Triumvira Immunologics Canada Inc. and Triumvira Immunologics USA Inc. today announced the appointment of Paul Lammers, M.D., M.Sc., as President and Chief Executive Officer. Dr. Lammers brings more than 27 years of experience in product and clinical development spanning the pharmaceutical and biotechnology industries.
“Paul is an experienced biopharmaceutical leader who has focused his career on trying to make a positive change in patients’ lives through the development of innovative drug therapies,” said Brian Bloom, CEO of Bloom Burton & Co, and Chairman and Co-Founder of Triumvira. “His experience in raising significant capital from leading strategic and traditional venture capitalists, as well as in building strong development and management teams, are invaluable assets to capture the opportunities that lie ahead for Triumvira.”
